NASHUA, N.H.and ATHENS, Greece,—iCAD, Inc.(NASDAQ: ICAD),a global medical technology leader providing innovative cancer detection and therapy solutions,today announced outstanding clinical results of its new, leading-edge digital breast tomosynthesis (DBT) cancer detection software. The study demonstrated significant positive results for clinical performance and workflow efficiency.